NurExone Logo Rebrand-large.png
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
05 févr. 2025 16h04 HE | NurExone Biologic Inc
NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.
NurExone Logo Rebrand-large.png
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
21 janv. 2025 16h20 HE | NurExone Biologic Inc
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
NurExone Logo Rebrand-large.png
NurExone Biologic Secures Master Cell Bank
08 janv. 2025 16h12 HE | NurExone Biologic Inc
NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production
Figures PR 0612
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
06 déc. 2024 16h03 HE | NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
NurExone Logo Rebrand-large.png
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
27 nov. 2024 07h01 HE | NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NurExone Logo Rebrand-large.png
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
13 nov. 2024 16h14 HE | NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
NurExone Logo Rebrand-large.png
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
01 nov. 2024 16h50 HE | NurExone Biologic Inc
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
NurExone Logo Rebrand-large.png
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
23 oct. 2024 02h56 HE | NurExone Biologic Inc
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences
NurExone Logo Rebrand-large.png
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
26 sept. 2024 16h03 HE | NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
NurExone Logo Rebrand-large.png
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
12 sept. 2024 16h04 HE | NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events